Approved for SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant. Esketamine, the S-enantiomer of racemic ketamine, is a non-selective,…
Loading full data from Know Your Drugs Institute…